Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 8/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HRH1 | P35367 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24058373 | 1.00 | DNM1 (0.33) | DNM1ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL22909000 | 0.92 | DNM1 (0.38) | DNM1ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL19519205 | 0.90 | DNM1 (0.42) | DNM1ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL26079812 | 0.90 | DNM1 (0.42) | DNM1ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL11412064 | 0.86 | NFKB1 (0.35) | DNM1ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL26720147 | 0.85 | DNM1 (0.31) | DNM1ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL26720171 | 0.83 | DNM1 (0.36) | DNM1ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL21126665 | 0.83 | — | — | |
| SCHEMBL5933640 | 0.83 | — | — | |
| SCHEMBL9191832 | 0.82 | TRPV1 (0.37) | DNM1ALDH1A1MEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190247839-A1 | MODIFIED POROUS ORGANIC FRAMEWORK AND MANUFACTURING METHOD THEREOF, POROUS ORGANIC FRAMEWORK COMPOSITE AND MANUFACTURING METHOD THEREOF | CHUNG YUAN CHRISTIAN UNIVERSITY (TW) | 2019-08-15 | — | — | US | disclosed |
| EP-2492265-A1 | 1,2,4-Thiadiazole Compounds and Pests Controlling Composition Containing the same | Sumitomo Chemical Company, Limited (JP) | 2012-08-29 | — | — | EP | disclosed |
| US-7371746-B2 | 1,2,4-Thiadiazole compounds and pests controlling composition containing the same | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2008-05-13 | — | — | US | disclosed |
| EP-1765798-A2 | 1,2,4- THIADIAZOLE COMPOUNDS AND PESTS CONTROLLING COMPOSITION CONTAINING THE SAME | Sumitomo Chemical Company, Limited (JP) | 2007-03-28 | — | — | EP | disclosed |
| US-20070004722-A1 | 1,2,4-Thiadazole compounds and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-01-04 | — | — | US | disclosed |
| WO-2005037805-A2 | 1,2,4-THIADIAZOLE COMPOUNDS AND PESTS CONTROLLING COMPOSITION CONTAINING THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-04-28 | — | — | WO | disclosed |
| US-20020128208-A1 | Nonpeptide agonists and antagonists of vasopressin receptors | EMORY UNIVERSITY | 2002-09-12 | — | — | US | disclosed |
| WO-2002047679-A2 | NONPEPTIDE AGONISTS AND ANTAGONISTS OF VASOPRESSIN RECEPTORS | EMORY UNIVERSITY (US) | 2002-06-20 | — | — | WO | disclosed |
| US-5614519-A | (1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists | KARL THOMAE GMBH (DE) | 1997-03-25 | — | — | US | disclosed |
| US-5602127-A | ADMINISTERING TO TREAT HYPERTENSION | KARL THOMAE GMBH (DE) | 1997-02-11 | — | — | US | disclosed |
| US-5594003-A | HYPOTENSIVE AGENTS | DR. KARL THOMAE GMBH (DE) | 1997-01-14 | — | — | US | disclosed |
| US-5591762-A | HYPOTENSIVE AGENTS | DR. KARL THOMAE GMBH (DE) | 1997-01-07 | — | — | US | disclosed |
| US-4027037-A | ARTHROPOD METAMORPHOSIS INHIBITORS | BAYER AKTIENGESELLSCHAFT (DT) | 1977-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004722-A1 | 1,2,4-Thiadazole compounds and use thereof | CYP4F3, CYP4B1, CYP4X1 | DNM1 3888/4885ALDH1A1 248/4885MEN1 2175/4885 |
| US-20020128208-A1 | Nonpeptide agonists and antagonists of vasopressin receptors | AVPR1A, AVPR2, AVPR1B | DNM1 906/4885ALDH1A1 3278/4885MEN1 1272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.